Core Viewpoint - Taihe Cheng Medical (CCM) experienced a stock price increase of 3.84% on August 5, closing at $5.545 per share, with a total market capitalization of $27.51 million [1] Financial Performance - As of December 31, 2024, Taihe Cheng Medical reported total revenue of 384 million RMB, a year-on-year decrease of 28.55% [1] - The company's net profit attributable to shareholders was -30.8 million RMB, reflecting a year-on-year decrease of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng entered into a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on various aspects such as diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to establish an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]

Core Insights - Taihe Cheng Medical (CCM) experienced an intraday increase of 8.43%, reaching a price of $5.4 per share, with a total market capitalization of $26.79 million [1] - As of December 31, 2024, the company's total revenue is projected to be 384 million RMB, reflecting a year-on-year decrease of 28.55%, while the net profit attributable to shareholders is expected to be -30.8 million RMB, a decline of 3.56% year-on-year [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, aiming to collaborate on diagnostic technology, radiation quality control, medical processes, operational management, brand usage in Singapore and mainland China, and the operation and training of proton centers [1] - The partnership focuses on building an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research orientation, enhancing patient experience and improving cancer treatment standards in China [1]

Core Viewpoint - Taihe Cheng Medical (CCM) experienced a 2.4% increase in stock price, reaching $5.345 per share, with a total market capitalization of $26.52 million as of July 30 [1] Financial Performance - As of December 31, 2024, Taihe Cheng Medical reported total revenue of 384 million RMB, a year-on-year decrease of 28.55% [1] - The company recorded a net profit attributable to shareholders of -30.8 million RMB, reflecting a year-on-year decline of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - Established in 1997, the company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to develop an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]

Core Insights - Concord Healthcare Group Co., Ltd. has successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma, marking a significant advancement in oncology care in the country [1][3]. Company Overview - Concord Medical Services Holdings Limited is a healthcare provider specializing in a full cycle of premium oncology services, including cancer diagnosis, treatment, education, and prevention [5]. - The company focuses on multidisciplinary cancer care and aims to improve the quality and accessibility of cancer treatment through its network of self-owned and partnered hospitals across China [5][6]. Treatment Innovation - The Guangzhou Concord Cancer Center employs advanced pencil beam scanning proton therapy combined with a real-time image guidance system, allowing for high-dose and precise irradiation while protecting surrounding healthy tissues [3]. - This innovative treatment option provides an eye-preserving alternative to traditional enucleation, which can lead to permanent blindness and other complications [2][3]. Market Position - As the first medical institution in China to offer proton therapy for choroidal malignant melanoma, Guangzhou Concord Cancer Center fills a critical gap in the oncology treatment landscape [3].

Core Viewpoint - Concord Healthcare Group has made significant advancements in precise tumor diagnosis and treatment technology, particularly with the launch of its self-developed large language model (LLM) for proton therapy, which has been successfully implemented in Guangzhou Concord Cancer Hospital [1][2]. Company Overview - Concord Medical Services Holdings Limited is a healthcare provider specializing in comprehensive oncology services, including cancer diagnosis, treatment, education, and prevention, with a focus on improving the quality and accessibility of cancer care across China [4]. - The company operates a network of self-owned cancer hospitals and clinics, equipped with advanced technology such as proton therapy systems, and aims to provide multidisciplinary cancer care [4]. Technology and Innovation - The proton LLM developed by Concord Healthcare is the first of its kind in China, utilizing a robust tumor diagnosis and treatment technology system built on extensive data accumulated over the years, including nearly 10,000 high-quality radiotherapy cases [2]. - The model integrates data from Proton China and professional journal literature to enhance its training and effectiveness in patient treatment [2]. Market Position - Concord Healthcare serves both cancer patients directly through its own medical institutions and indirectly through third-party medical institutions by providing medical equipment, software, and related services [5]. - The company has established a widespread network of enterprise customers, primarily hospitals, offering integrated oncology-related services, including sales and installation of medical equipment, management, technical support, and operating leases [5].

Financial Performance - As of June 30, 2024, the total revenue of Taihe Cheng Medical (CCM) is 219 million RMB, representing a year-on-year decrease of 23.09% [1] - The net profit attributable to the parent company is -172 million RMB, showing a significant year-on-year decline of 89.33% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [2] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [2] - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center to enhance cancer treatment and research capabilities in China and Singapore [2]

Core Viewpoint - Concord Medical Services Holdings Limited has filed its annual report for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission, highlighting its commitment to transparency and regulatory compliance [1]. Company Overview - Concord Medical is a healthcare provider specializing in a full cycle of premium oncology services, including cancer diagnosis, treatment, education, and prevention [2]. - The company focuses on multidisciplinary cancer care and operates cancer hospitals equipped with advanced technology, such as a state-of-the-art proton therapy system [2]. - Concord Medical aims to enhance the quality and accessibility of cancer care through its network of self-owned and partnered hospitals and clinics across China [2].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

Core Viewpoint - Concord Medical Services Holdings Limited, a healthcare provider specializing in cancer treatment, announced the adoption of the Fifth Amended and Restated Memorandum and Articles of Association during its 2024 annual general meeting of shareholders held on December 27, 2024 [1]. Group 1: Company Overview - Concord Medical provides a full cycle of premium oncology services, including cancer diagnosis, treatment, education, and prevention [2]. - The company focuses on multidisciplinary cancer care and operates cancer hospitals equipped with advanced technology, such as a state-of-the-art proton therapy system [2]. - Concord Medical aims to enhance the quality and accessibility of cancer care through its network of self-owned hospitals and partnered facilities across China [2].

Group 1 - Concord Medical Services Holdings Limited will hold its 2024 annual general meeting of shareholders on December 27, 2024, at 10:00 a.m. Beijing Time [1] - The purpose of the meeting includes amending the Company's memorandum and articles of association to reflect the change in the ratio of its American depositary shares to Class A ordinary shares, effective July 30, 2024 [2] - Shareholders will have the opportunity to discuss Company affairs with management during the meeting [2] Group 2 - Concord Medical is a healthcare provider specializing in a full cycle of premium oncology services, including cancer diagnosis, treatment, education, and prevention [3] - The Company aims to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics, as well as partnered hospitals across China [3] - Concord Medical is equipped with technologically advanced equipment, such as a state-of-the-art proton therapy system [3]